Heartseed, Inc. (JP:219A)
:219A
Want to see JP:219A full AI Analyst Report?
219A Stock Chart & Stats
¥1804.00
-¥95.00(-2.73%)
At close: 4:00 PM EST
¥1804.00
-¥95.00(-2.73%)
Day’s Range― - ―
52-Week Range¥1,343.00 - ¥4,385.00
Previous CloseN/A
Volume1.41M
Average Volume (3M)738.74K
Market Cap
¥40.78B
Enterprise Value¥31.53B
Total Cash (Recent Filing)¥7.34B
Total Debt (Recent Filing)¥890.00K
Price to Earnings (P/E)―
Beta1.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,874,200
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base provide durable financial flexibility, reducing insolvency risk and enabling the firm to fund clinical programs or partnerships without needing frequent high-cost debt. This strengthens long-term resilience through funding cycles and shocks.
Return To Positive Cash GenerationA sustained shift to positive operating and free cash flow materially lowers dependence on external capital and dilutive financings. If maintained, it supports continued R&D investment, milestone-driven partnerships and grants, and gives management real optionality for strategic growth.
Platform Addressing Large Unmet NeedA focused regenerative platform targeting severe heart failure represents a structural market opportunity with durable clinical demand. Platform-based stem-cell approaches can generate recurring licensing, royalties and partnership revenue streams, enhancing long-term commercial optionality.
Bears Say
Historic Multi-Year LossesA recent multi-year history of steep losses and cash burn demonstrates execution and commercialization risk; earnings have been volatile. If growth or cash generation falters, the company may revert to funding dependence or dilution, undermining long-term capital efficiency.
Inconsistent Gross Profit ReportingIrregular gross profit presentation and a reported zero gross profit in FY2025 reduce confidence in margin comparability and obscure core product economics. This complicates sustainable margin modeling and heightens execution risk when scaling commercial operations.
Dependence On External Funding/PartnershipsA business model reliant on partnerships, milestone payments and external grants creates structural revenue variability and funding risk. Long-term plans hinge on securing partner deals or continued external capital, which can be episodic and affect development timelines and cash predictability.
Heartseed, Inc. News
219A FAQ
What was Heartseed, Inc.’s price range in the past 12 months?
Heartseed, Inc. lowest stock price was ¥1343.00 and its highest was ¥4385.00 in the past 12 months.
What is Heartseed, Inc.’s market cap?
Heartseed, Inc.’s market cap is ¥40.78B.
When is Heartseed, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Heartseed, Inc.’s earnings last quarter?
Currently, no data Available
Is Heartseed, Inc. overvalued?
According to Wall Street analysts Heartseed, Inc.’s price is currently Overvalued.
Does Heartseed, Inc. pay dividends?
Heartseed, Inc. does not currently pay dividends.
What is Heartseed, Inc.’s EPS estimate?
Heartseed, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heartseed, Inc. have?
Heartseed, Inc. has 22,874,200 shares outstanding.
What happened to Heartseed, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Heartseed, Inc.?
Currently, no hedge funds are holding shares in JP:219A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heartseed, Inc.
Heartseed, Inc. engages in the provision of cardiac regenerative medicine. The company was founded by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa and Yutaro Kasai on November 30, 2015 and is headquartered in Tokyo, Japan.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Medical System Network Co., Ltd.
―
Shinnihonseiyaku Co., Ltd.
―
Chordia Therapeutics Inc.
―